Modified CEA/B7 vector
The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
1. An expression vector comprising the nucleic acid sequence of SEQ ID No. 6 and a nucleic acid sequence encoding human B7.1.
2. The expression vector of claim 1 wherein the human B7.1 is encoded by nucleotides 792-1658 of SEQ ID NO. 11.
3. The expression vector of claim 1 wherein the vector is a plasmid or a viral vector.
4. The expression vector of claim 3 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
5. The expression vector of claim 4 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
6. The expression vector of claim 3 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, Modified Vaccinia Virus Ankara (MVA), NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
7. The expression vector of claim 6 further comprising at least one additional nucleotide sequence encoding a tumor associated antigen.
8. The expression vector of claim 6 wherein the poxvirus is avipox.
9. The expression vector of claim 8 wherein the avipox is ALVAC or ALVAC(2).
10. The expression vector of claim 9 wherein the avipox is ALVAC(2).
11. An isolated DNA molecule comprising the nucleic acid sequence of SEQ ID No. 6 and a nucleotide sequence encoding human B7.1.
12. The DNA molecule vector of claim 11 wherein the human B7.1 is encoded by nucleotides 792-1658 of SEQ ID NO. 11.